437 related articles for article (PubMed ID: 15632471)
1. [Osteoclastogenesis Inhibitory Factor (OCIF) /Osteoprotegerin (OPG) as a new therapeutic agent for osteoporosis].
Mochizuki S; Kiyokawa A; Nagayama Y
Clin Calcium; 2005 Jan; 15(1):35-42. PubMed ID: 15632471
[TBL] [Abstract][Full Text] [Related]
2. Osteoprotegerin and its ligand: A new paradigm for regulation of osteoclastogenesis and bone resorption.
Aubin JE; Bonnelye E
Medscape Womens Health; 2000 Mar; 5(2):5. PubMed ID: 10792853
[TBL] [Abstract][Full Text] [Related]
3. Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis.
Takayanagi H; Iizuka H; Juji T; Nakagawa T; Yamamoto A; Miyazaki T; Koshihara Y; Oda H; Nakamura K; Tanaka S
Arthritis Rheum; 2000 Feb; 43(2):259-69. PubMed ID: 10693864
[TBL] [Abstract][Full Text] [Related]
4. A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function.
Takahashi N; Udagawa N; Suda T
Biochem Biophys Res Commun; 1999 Mar; 256(3):449-55. PubMed ID: 10080918
[TBL] [Abstract][Full Text] [Related]
5. [Osteoclastogenesis inhibitory factor (OCIF)/osteoprotegerin (OPG)].
Okada F; Tsuda E
Clin Calcium; 2002 Aug; 12(8):1157-64. PubMed ID: 15775414
[TBL] [Abstract][Full Text] [Related]
6. RANK-Fc: a therapeutic antagonist for RANK-L in myeloma.
Sordillo EM; Pearse RN
Cancer; 2003 Feb; 97(3 Suppl):802-12. PubMed ID: 12548579
[TBL] [Abstract][Full Text] [Related]
7. Osteoprotegerin and its ligand: a new paradigm for regulation of osteoclastogenesis and bone resorption.
Aubin JE; Bonnelye E
Osteoporos Int; 2000; 11(11):905-13. PubMed ID: 11193242
[TBL] [Abstract][Full Text] [Related]
8. [Osteoclastogenesis inhibitory factor/osteoprotegerin(OCIF/OPG)].
Tomoyasu A; Higashio K
Nihon Rinsho; 2004 Feb; 62 Suppl 2():560-5. PubMed ID: 15035190
[No Abstract] [Full Text] [Related]
9. Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin.
Collin-Osdoby P
Circ Res; 2004 Nov; 95(11):1046-57. PubMed ID: 15564564
[TBL] [Abstract][Full Text] [Related]
10. Crystal structure of RANK ligand involved in bone metabolism.
Ito S; Hata T
Vitam Horm; 2004; 67():19-33. PubMed ID: 15110169
[TBL] [Abstract][Full Text] [Related]
11. Novel aspects on RANK ligand and osteoprotegerin in osteoporosis and vascular disease.
Sattler AM; Schoppet M; Schaefer JR; Hofbauer LC
Calcif Tissue Int; 2004 Jan; 74(1):103-6. PubMed ID: 14523602
[TBL] [Abstract][Full Text] [Related]
12. [OPG, anti-rANKL antibody].
Yasuda H
Nihon Rinsho; 2005 Sep; 63(9):1647-53. PubMed ID: 16164225
[TBL] [Abstract][Full Text] [Related]
13. Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells.
Shipman CM; Croucher PI
Cancer Res; 2003 Mar; 63(5):912-6. PubMed ID: 12615702
[TBL] [Abstract][Full Text] [Related]
14. [New paradigms in the regulation of bone metabolism].
Rosa-Rañal M; de la Cruz DA; Lorena-Rubio Y; Larrea F
Rev Invest Clin; 2001; 53(4):362-9. PubMed ID: 11599485
[TBL] [Abstract][Full Text] [Related]
15. Interactive effect of interleukin-6 and prostaglandin E2 on osteoclastogenesis via the OPG/RANKL/RANK system.
Liu XH; Kirschenbaum A; Yao S; Levine AC
Ann N Y Acad Sci; 2006 Apr; 1068():225-33. PubMed ID: 16831922
[TBL] [Abstract][Full Text] [Related]
16. Alpha-lipoic acid suppresses osteoclastogenesis despite increasing the receptor activator of nuclear factor kappaB ligand/osteoprotegerin ratio in human bone marrow stromal cells.
Koh JM; Lee YS; Byun CH; Chang EJ; Kim H; Kim YH; Kim HH; Kim GS
J Endocrinol; 2005 Jun; 185(3):401-13. PubMed ID: 15930166
[TBL] [Abstract][Full Text] [Related]
17. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption.
Hofbauer LC; Khosla S; Dunstan CR; Lacey DL; Boyle WJ; Riggs BL
J Bone Miner Res; 2000 Jan; 15(1):2-12. PubMed ID: 10646108
[TBL] [Abstract][Full Text] [Related]
18. [Clinical implications of new insights into the regulation of bone resorption].
Lems WF; Bijlsma JW
Ned Tijdschr Geneeskd; 2005 Jul; 149(30):1664-7. PubMed ID: 16104110
[TBL] [Abstract][Full Text] [Related]
19. Osteoprotegerin and inflammation.
Saidenberg Kermanac'h N; Bessis N; Cohen-Solal M; De Vernejoul MC; Boissier MC
Eur Cytokine Netw; 2002; 13(2):144-53. PubMed ID: 12101070
[TBL] [Abstract][Full Text] [Related]
20. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis.
Nakagawa N; Kinosaki M; Yamaguchi K; Shima N; Yasuda H; Yano K; Morinaga T; Higashio K
Biochem Biophys Res Commun; 1998 Dec; 253(2):395-400. PubMed ID: 9878548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
